Effect of the Α-Glucosidase Inhibitor Miglitol on the Glucose Profile in Japanese Type 2 Diabetic Patients Receiving Multiple Daily Insulin Injections

Total Page:16

File Type:pdf, Size:1020Kb

Effect of the Α-Glucosidase Inhibitor Miglitol on the Glucose Profile in Japanese Type 2 Diabetic Patients Receiving Multiple Daily Insulin Injections Endocrine Journal 2012, 59 (4), 345-352 ORIGINAL Effect of the α-glucosidase inhibitor miglitol on the glucose profile in Japanese type 2 diabetic patients receiving multiple daily insulin injections Hiroyuki Kato, Akio Ohta, Suzuko Kobayashi, Satoshi Ishii, Yukiyoshi Sada, Hidetoshi Kobayashi, Shintaro Ohmori, Akihiko Kondo, Takuyuki Katabami, Junro Fuse, Hisashi Fukuda, Yoshio Nagai and Yasushi Tanaka Department of Internal Medicine, Division of Metabolism and Endocrinology, St. Marianna University School of Medicine, Kawasaki 216-8511, Japan Abstract. Strict postprandial glycemic control may have a preventive effect on atherogenesis in patients with type 2 diabetes. The α-glucosidase inhibitor (α-GI) miglitol is useful for controlling the early postprandial increase of glucose, but the combined effect of miglitol and multiple daily insulin injections (MDI) on glucose excursion has not been evaluated. First, we retrospectively compared the daily glucose profile, evaluated by self-monitoring of blood glucose (SMBG) at nine times on the day before discharge from hospital, between type 2 diabetic patients receiving MDI (n=81) or MDI plus miglitol at 150 mg daily (n=24). Second, we prospectively examined the effect of adding miglitol to MDI on the daily glucose profile (SMBG) in 19 other type 2 diabetic patients. Although the daily insulin dosage and the glucose level before meals did not differ between the two groups, the 1-h postprandial glucose level after each meal, 2-h glucose level after lunch and dinner, mean and standard deviation of glucose, and amplitude of glucose excursion were significantly lower or smaller in the MDI plus miglitol group than in the MDI group. All of these glucose parameters were significantly improved by adding miglitol to MDI in the prospective cohort of 19 patients. In conclusion, adding miglitol to MDI reduces postprandial glucose levels and attenuates daily glucose fluctuation in type 2 diabetic patients. This trial was registered with UMIN (no. UMIN000005383). Key words: Daily glucose profile, Miglitol, Multiple daily insulin injections THE POSTPRANDIAL plasma glucose level is patients undergoing prospective follow up for 5 years thought to be a risk factor for the cardiovascular com- [5]. Recently, Esposito et al. reported that the post- plications of diabetes independently of fasting plasma prandial peak glucose level determined by self-moni- glucose (FPG) [1-3]. Hanefeld et al. found that the 1-h toring of blood glucose (SMBG) at home was associ- postprandial glucose level after breakfast, but not FPG, ated with carotid artery intima-media thickness (IMT), was a risk factor for myocardial infarction in an 11-year a surrogate marker of atherosclerosis, independently of prospective study of patients with newly diagnosed hemoglobin A1c (HbA1c) in type 2 diabetic patients [6], non-insulin dependent diabetes mellitus (NIDDM) and that there was an incremental glucose peak within [4]. Another study showed that the 2-h postprandial 1 hour of starting either main meal (lunch or dinner). glucose level after lunch, but not FPG, was a strong Similarly, Hu et al. showed that the postchallenge glu- predictor of cardiovascular events in type 2 diabetic cose spike (the difference between the maximal plasma glucose level during a 75 g oral glucose tolerance test Submitted Oct. 6, 2011; Accepted Jan. 19, 2012 as EJ11-0283 and the baseline fasting plasma glucose level) was Released online in J-STAGE as advance publication Feb. 2, 2012 associated with carotid artery IMT independently of Correspondence to: Akio Ohta, M.D., Department of Internal HbA1c in type 2 diabetic patients [7]. Although post- Medicine, Division of Metabolism and Endocrinology, St. Marianna University School of Medicine, 2-16-1 Sugao, Miyamae- prandial glucose levels were not measured after every ku, Kawasaki, Kanagawa 216-8511, Japan meal in these studies, the findings imply that control- E-mail: [email protected] ling excessive early postprandial hyperglycemia could ©The Japan Endocrine Society 346 Kato et al. help to prevent cardiovascular complications. as the National Glycohemoglobin Standardizaion Rapid-acting insulin preparations, such as Insulin Program (NGSP) equivalent value, which was calcu- Aspart or Insulin Lyspro, are useful to improve post- lated as HbA1C (NGSP) (%) = HbA1C (JDS) (%) + 0.4%, prandial hyperglycemia, since these insulins have sub- based on the relationship of HbA1C (NGSP) values to stituted amino acids at position 28 and/or 29 and are HbA1C (JDS) (%) values measured with the Japanese absorbed more quickly to act more rapidly than reg- standard and measurement method [12]. Serum GA ular human insulin [8, 9]. The α-glucosidase inhibi- was measured by an enzymatic method using an albu- tor (α-GI) miglitol is a unique oral antidiabetic agent min-specific protease (ketoamine oxidase) and an albu- that suppresses the early postprandial increase of glu- min assay reagent (Lucica GA-L, Asahi Kasei Pharma, cose more potently than other α-GIs, since miglitol is Tokyo, Japan). All patients were given instructions absorbed from the small intestine after oral administra- about how to perform SMBG with a One Touch Ultra tion and has a stronger action especially in the proxi- (Johnson and Johnson KK, Tokyo, Japan) by educa- mal small bowel [10, 11]. However, it remains unclear tional nurses. All patients started MDI after admis- whether the combination of miglitol and a rapid-act- sion, and their insulin dosage was adjusted to achieve ing insulin analog can further improve the early post- a glucose level <140 mg/dL, <200 mg/dL, and <180 prandial glucose profile compared with insulin alone. mg/dL before, 1 h after, and 2 h after meals, respec- In the present study, we retrospectively compared tively, in the absence of hypoglycemia (<70 mg/dL). the daily glucose profile obtained by SMBG between When the 1-h or 2-h postprandial glucose target could type 2 diabetic patients receiving multiple daily insu- not be achieved by MDI within one week after hospi- lin injections (MDI), i.e., rapid-acting insulin (Insulin talization despite reaching a preprandial glucose <140 Aspart or Insulin Lyspro) before each meal and long mg/dL, miglitol was added at 150 mg daily (50 mg - acting insulin (Insulin Glargine or Insulin Detemir) just before each meal). Other oral antidiabetic agents before bedtime, without an α-GI versus MDI plus were not changed during admission. All patients per- miglitol. In addition, we prospectively evaluated the formed SMBG at nine times (before each meal and 1 effect of adding miglitol to MDI on the daily glucose h and 2 h after each meal) on the day before discharge, profile (SMBG) in other type 2 diabetic patients. and the daily glucose profile of the patients treated by MDI alone (MDI group, n=81) was compared with that Materials and Methods of patients receiving MDI plus miglitol (MDI + Mig group, n=24). Subjects A total of 124 patients with type 2 diabetes admit- Effect of combined therapy on postprandial glucose ted to St. Marianna University Hospital (Kanagawa, In 19 patients receiving MDI who had stable pre- Japan) in 2009-2010 were studied, including 71 men prandial glucose levels <140 mg/dL, but inadequate and 53 women aged 60 ± 12 years (mean ± SD). They postprandial glycemic control, miglitol was added at were admitted to hospital for diabetes education and 150 mg daily (50 mg just before each meal) without improvement of glycemic control, and achieved good changing the insulin dosage. Other oral antidiabetic control by MDI with a glucose level of <140 mg/dL agents were not changed. To evaluate the effect of add- before each meal. The inclusion for this study crite- ing miglitol on the glucose profile, SMBG was done at rion was a glucose level <140 mg/dL before each meal nine time points on the day before and 7 or 8 days after without any symptoms of hypoglycemia throughout starting miglitol. the day. The exclusion criteria were pregnancy, any severe illness, chronic liver disease, thyroid disease, Statistical analysis malignancy, and a history of abdominal surgery. All Results are presented as the mean ± SD. Comparison patients gave written informed consent and the study of mean values was done by the paired or unpaired was approved by the Ethics Committee of St. Marianna t-test. All analyses were performed with Stat-View University School of Medicine (No. 1226). software (Abacus Concepts, Berkeley, CA) and statis- tical significance was accepted atp <0.05. Comparison of MDI with MDI plus miglitol On the day of admission, HbA1C (%) was estimated Miglitol with multiple insulin injections 347 Results of glucose excursion were lower or smaller in patients treated with MDI plus miglitol than in patients receiv- Retrospective study ing MDI alone, although there was no difference of The clinical profile on admission and a compari- their daily insulin dosage. Adding miglitol to MDI son of the daily insulin dose and glucose excursion decreased the early postprandial glucose surge after between the two treatment groups on the day before each meal, even in patients who had not achieved good discharge are shown in Table 1. The age, gender, BMI, postprandial glucose levels with MDI, resulting in HbA1c, and GA did not differ between the two groups reduction of the mean, SD, and amplitude of glucose. on admission. The daily dosages of rapid-acting and Our results suggested that combined therapy with MDI long - acting insulin, as well as the total insulin dose, plus miglitol achieves better control of glucose excur- also did not differ between the two groups. However, sion compared with MDI alone. Physicians some- both the mean and SD of the daily glucose level were times encounter patients without a decrease of the 1-h significantly lower in the MDI + Mig group than in the postprandial glucose level despite an increase of their MDI group on the day before discharge, and the ampli- insulin dose.
Recommended publications
  • Treatment of Diabetes Mellitus
    TREATMENT OF DIABETES MELLITUS DIABETES is a condition that affects how the body makes energy from food. Food is broken down into sugar (glucose) in the body and released into the blood. When the blood sugar level rises after a meal, insulin responds to let the sugar into the cells to be used as energy. In diabetes, the body either does not make enough insulin or it stops responding to insulin as well as it should. This results in sugar staying in the blood and leads to serious health problems over time. DIAGNOSIS OF DIABETES1 • A1C Test: Lab test measuring average blood sugar over past two to three months • Fasting Blood Sugar Test: Lab test measuring blood sugar after eight hours of no food or drink • Oral Glucose Tolerance Test (OGTT): Measures blood sugar before and two hours after drinking a specific sugary liquid • Random Blood Sugar Test: Measures blood sugar at a moment in time, without any kind of preparation (like fasting) FASTING BLOOD ORAL GLUCOSE TOLERANCE RANDOM BLOOD RESULT A1C TEST SUGAR TEST TEST SUGAR TEST Diabetes ≥ 6.5% ≥126 mg/dL ≥ 200 mg/dL ≥ 200 mg/dL Prediabetes 5.7 – 6.4% 100 – 125 mg/dL 140 – 199 mg/dL N/A Normal < 5.7% ≤99 mg/dL < 140 mg/dL N/A NON-DRUG TREATMENTS2 THERAPY COST WHAT TO EXPECT Diet (Mediterranean diet) and exercise (30 minutes a day, five days a week of moderate- Weight loss $-$$ intensity exercise); 7% weight loss decreases risk of diabetes3 Psychological intervention $$-$$$ Psychotherapy may reduce diabetic distress and improve glycemic control4,5 nationalcooperativerx.com PRESCRIPTION TREATMENTS
    [Show full text]
  • 295-304 Research Article Pulsatile Drug Delivery of Chitosan Co
    Available online www.jocpr.com Journal of Chemical and Pharmaceutical Research, 2015, 7(12):295-304 ISSN : 0975-7384 Research Article CODEN(USA) : JCPRC5 Pulsatile drug delivery of chitosan coated beads of miglitol with fast dissolving glimepiride tablet Bhise S. H.*, Surve B. S., Aloorkar N. H., Majumdar S. H. and Kulkarni A. S. Department of Pharmaceutics, Satara College of Pharmacy, Satara, Shivaji University, Maharashtra, India _____________________________________________________________________________________________ ABSTRACT : Pulsatile drug delivery system was developed which have three parts fast dissolving tablet of glimepiride, sustained release chitosan coated microbeads of miglitol and plug of HPMC E5 and spray dried lactose. After pre- formulation studies fast dissolving tablets were prepared by direct compression method; which shows instant drug release and % CDR of glimepiride fast dissolving tablet was found to be 70.81%. polymer plug have lag time 2.30 hr, chitosan coated miglitol beads shows sustained release upto 81.66% .this system is evaluated using different physicochemical parameters and in-vitro studies. Result suggests that the system can be applicable for diabetes treatment. Key words: Pulsatile, microbeads, sustained release, miglitol, glimepiride. _____________________________________________________________________________________________ INTRODUCTION Oral controlled drug delivery systems represent the most popular form of controlled drug delivery system which release the drug with constant or variable release rates.[1] Dose of drug, reduced dosage frequency, avoidance of side effects, and improved patient compliance. However, there are certain conditions for which such a release pattern is not suitable. These conditions demand release of drug after a lag time. In other words, it is required that the drug should not be released at all during the initial phase of dosage form administration.
    [Show full text]
  • Hypoglycemia in Diabetes: Common, Often Unrecognized
    REVIEW ILAN GABRIELY, MD HARRY SHAMOON, MD CME Diabetes Research Center, Albert Einstein Professor of Medicine, Diabetes Research CREDIT College of Medicine, New York Center, Albert Einstein College of Medicine, New York Hypoglycemia in diabetes: Common, often unrecognized ■ ABSTRACT YPOGLYCEMIA poses a major barrier to H diabetes treatment. On one hand, we Hypoglycemic episodes in patients with diabetes often go want to maintain tight glycemic control to unrecognized, and over time, patients may lose the ability prevent the vascular complications of diabetes, to sense hypoglycemia, increasing their risk. Intensive but we also have to ensure the safety and com- diabetes control is beneficial for patients with diabetes, fort of the patient by avoiding hypoglycemia— but it increases their risk of hypoglycemia, underscoring and by recognizing and treating it if it occurs. the complexity of diabetes management. Hypoglycemic events are probably com- mon, especially in patients with type 1 diabetes. ■ KEY POINTS And when patients with type 2 diabetes receive insulin, they may become more prone to hypo- Epinephrine release during hypoglycemia becomes glycemic episodes. Unfortunately, the more progressively defective in type 1 diabetes. This decrease in episodes of hypoglycemia a patient has, the epinephrine response is accompanied by an attenuated more the body’s response is blunted, decreasing autonomic neural response, which results in the clinical the patient’s awareness of an episode. syndrome of impaired awareness of hypoglycemia (ie, Thus, we need to be vigilant in monitor- lack of the warning symptoms of prevailing ing patients for increasing episodes of hypo- glycemia, and for events that a patient may not hypoglycemia).
    [Show full text]
  • Women with Higher BMI at Lower Risk for Glaucoma
    44 WOMEN'S HEALTH SEPTEMBER 1, 2010 • FAMILY PRACTICE NEWS DRUGS, PREGNANCY, AND LACTATION Use of Antidiabetic Agents During Pregnancy n a previous column, I looked at the abinese), tolazamide (Tolinase), and tolbu- thetic analogue of human amylin given was discovered. No developmental toxi- ways uncontrolled hyperglycemia tamide (Orinase). They can cause marked by subcutaneous injection, but the ani- city was observed in the newborns. Iduring pregnancy causes significant and persistent neonatal hypoglycemia if mal data suggest moderate risk (struc- Pioglitazone (Actos) and rosiglitazone toxicity for the mother, embryo, fetus, taken close to birth. To prevent this toxi- tural anomalies in rats). The drug— (Avandia), thiazolidinediones used as ad- newborn, and adolescent (“Toxicity of city, therapy should be changed to insulin which slows the rate of gastric emptying, juncts to diet and exercise, lower insulin Diabetes in Pregnancy,” December in the third trimester or, at least, several prevents a postprandial rise in plasma resistance but do not promote insulin re- 2009, p. 52). days before birth. glucagon, and promotes satiety—is best lease. Animal reproduction data suggest This column examines the The second-generation sul- avoided in pregnancy. risk, but the human experience is too use of antidiabetic agents, fonylureas glipizide (Glu- Saxagliptin (Onglyza) and sitagliptin limited to assess the risk, so they should other than insulin, that are cotrol), glimepiride (Amaryl), (Januvia), inhibitors of the enzyme be avoided in pregnancy. used for non–insulin-depen- and glyburide (DiaBeta, Gly- dipeptidyl peptidase–4, are indicated as In summary, only metformin and gly- dent diabetes during preg- nase, and Micronase) are pre- monotherapy or in combination with buride have sufficient human pregnancy nancy and lactation.
    [Show full text]
  • Comparative Review of Oral Hypoglycemic Agents in Adults
    SECTION 18.5 Comparative Review of Oral Hypoglycemic Agents in Adults Harinder Chahal For WHO Secretariat Table of Contents Acronyms: ............................................................................................................................................................................... 3 I. Background and Rationale for the review: ....................................................................................................................... 4 II. Medications under comparative review: ......................................................................................................................... 4 Table 1 - New oral hypoglycemic agents for comparison with current EML agents .......................................................... 5 III. Literature searches and methodology: ............................................................................................................................ 5 1. Title Search Results: .................................................................................................................................................... 6 2. Statement about quality of evidence: ........................................................................................................................ 6 IV. Clinical efficacy and safety evaluation: ............................................................................................................................ 6 1. DPP-4 Inhibitors (Sitagliptin, Saxagliptin) and Metformin: ........................................................................................
    [Show full text]
  • Oral Health Fact Sheet for Dental Professionals Adults with Type 2 Diabetes
    Oral Health Fact Sheet for Dental Professionals Adults with Type 2 Diabetes Type 2 Diabetes ranges from predominantly insulin resistant with relative insulin deficiency to predominantly an insulin secretory defect with insulin resistance, American Diabetes Association, 2010. (ICD 9 code 250.0) Prevalence • 23.6 million Americans have diabetes – 7.8% of U.S. population. Of these, 5.7 million do not know they have the disease. • 1.6 million people ≥20 years of age are diagnosed with diabetes annually. • 90–95% of diabetic patients have Type 2 Diabetes. Manifestations Clinical of untreated diabetes • High blood glucose level • Excessive thirst • Frequent urination • Weight loss • Fatigue Oral • Increased risk of dental caries due to salivary hypofunction • Accelerated tooth eruption with increasing age • Gingivitis with high risk of periodontal disease (poor control increases risk) • Salivary gland dysfunction leading to xerostomia • Impaired or delayed wound healing • Taste dysfunction • Oral candidiasis • Higher incidence of lichen planus Other Potential Disorders/Concerns • Ketoacidosis, kidney failure, gastroparesis, diabetic neuropathy and retinopathy • Poor circulation, increased occurrence of infections, and coronary heart disease Management Medication The list of medications below are intended to serve only as a guide to facilitate the dental professional’s understanding of medications that can be used for Type 2 Diabetes. Medical protocols can vary for individuals with Type 2 Diabetes from few to multiple medications. ACTION TYPE BRAND NAME/GENERIC SIDE EFFECTS Enhance insulin Sulfonylureas Glipizide (Glucotrol) Angioedema secretion Glyburide (DiaBeta, Fluconazoles may increase the Glynase, Micronase) hypoglycemic effect of glipizide Glimepiride (Amaryl) and glyburide. Tolazamide (Tolinase, Corticosteroids may produce Diabinese, Orinase) hyperglycemia. Floxin and other fluoroquinolones may increase the hypoglycemic effect of sulfonylureas.
    [Show full text]
  • Diabetes Recommendations and Tier Coverage Chart
    DIABETES RECOMMENDATIONS AND TIER COVERAGE CHART The American Diabetes Association guidelines for 2020, recommend metformin as the preferred initial treatment for type 2 diabetes (T2DM) along with weight management and physical activity. In patients who have established ASVD or at high risk, CKD, or HF, a SGLT2i or GLP-1 receptor with proven efficacy is recommended independent of A1C. • ASCVD dominates: o GLP-1RA with proven CVD benefit (dulaglutide, liraglutide, injectable semaglutide) OR o SGLT2i with proven CVD benefit (canagliflozin, empagliflozin) if adequate eGFR • HF or CKD dominates: o SGLT2i with evidence of reducing HF and/or CKD progression (empagliflozin, canagliflozin, dapagliflozin) if adequate eGFR OR o If SGLT2i intolerant/contraindicated or eGFR is inadequate, then GLP-1RA with proven CVD benefit In individuals without established cardiovascular disease, pharmacological treatment should be patient-centered taking into account side-effects, cost, impact on weight, risk of hypoglycemia, and other patient preferences. For more detailed information regarding ADA recommendations for pharmacological agents to treat T2DM click here. The following chart is a list of oral and injectable diabetes medications listed by class with their respective A1C reduction and insurance coverage and/or coverage requirements for BCBS, HPHC, Tufts, TMP, and MassHealth. Tufts Medicare Medications BCBSMA HPHC Tufts Preferred MassHealth Biguanides A1C reduction: 1-1.5% metformin Tier 1 Tier 1;2 Tier 1 Tier 1 Covered Glucoghage (metformin) NC NC NC;Tier
    [Show full text]
  • The Synergistic Effect of Miglitol Plus Metformin Combination Therapy in the Treatment of Type 2 Diabetes
    Clinical Care/Education/Nutrition ORIGINAL ARTICLE The Synergistic Effect of Miglitol Plus Metformin Combination Therapy in the Treatment of Type 2 Diabetes 1 JEAN-LOUIS CHIASSON, MD The recently developed class of 2 LISA NADITCH, MD ␣-glucosidase inhibitors has a unique FOR THE MIGLITOL CANADIAN UNIVERSITY mode of action; it blocks oligosaccharide INVESTIGATOR GROUP catabolism, delays carbohydrate diges- tion and absorption, and smooths and lowers postprandial plasma blood glu- cose peaks (6–9). Substantial evidence supports their use as monotherapy or ad- OBJECTIVE — To investigate the efficacy and safety of miglitol in combination with met- junct therapy for poorly controlled type 2 formin in improving glycemic control in outpatients in whom type 2 diabetes is insufficiently diabetes (5,10–14). Miglitol is the first controlled by diet alone. pseudomonosaccharide ␣-glucosidase in- RESEARCH DESIGN AND METHODS — In this multicenter, double-blind, placebo- hibitor derived from 1-deoxynojirimycin controlled study, 324 patients with type 2 diabetes were randomized, after an 8-week placebo and is structurally a glucose analog run-in period, to treatment with either placebo, miglitol alone, metformin alone, or miglitol plus (15,16). Its efficacy in monotherapy metformin for 36 weeks. The miglitol was titrated to 100 mg three times a day and metformin was (13,17) and in combination with sulfo- administered at 500 mg three times a day. The primary efficacy criterion was change in HbA1c nylureas (11) as a glucose-lowering agent from baseline to the end of treatment. Secondary parameters included changes in fasting and in type 2 diabetes has been shown in a postprandial plasma glucose and insulin levels, serum triglyceride levels, and responder rate.
    [Show full text]
  • 8. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes—2018
    Diabetes Care Volume 41, Supplement 1, January 2018 S73 8. Pharmacologic Approaches to American Diabetes Association Glycemic Treatment: Standards of Medical Care in Diabetesd2018 Diabetes Care 2018;41(Suppl. 1):S73–S85 | https://doi.org/10.2337/dc18-S008 8. PHARMACOLOGIC APPROACHES TO GLYCEMIC TREATMENT The American Diabetes Association (ADA) “Standards of Medical Care in Diabetes” includes ADA’s current clinical practice recommendations and is intended to provide the components of diabetes care, general treatment goals and guidelines, and tools to evaluate quality of care. Members of the ADA Professional Practice Committee, a multidisciplinary expert committee, are responsible for updating the Standards of Care annually, or more frequently as warranted. For a detailed description of ADA standards, statements, and reports, as well as the evidence-grading system for ADA’s clinical practice recommendations, please refer to the Standards of Care Introduction. Readers who wish to comment on the Standards of Care are invited to do so at professional.diabetes.org/SOC. PHARMACOLOGIC THERAPY FOR TYPE 1 DIABETES Recommendations c Most people with type 1 diabetes should be treated with multiple daily in- jections of prandial insulin and basal insulin or continuous subcutaneous insulin infusion. A c Most individuals with type 1 diabetes should use rapid-acting insulin analogs to reduce hypoglycemia risk. A c Consider educating individuals with type 1 diabetes on matching prandial insulin doses to carbohydrate intake, premeal blood glucose levels, and anticipated physical activity. E c Individuals with type 1 diabetes who have been successfully using continuous subcutaneous insulin infusion should have continued access to this therapy after they turn 65 years of age.
    [Show full text]
  • Medications Used to Treat Type 2 Diabetes
    Medications Used to Treat Type 2 Diabetes This handout shows the different medications that your healthcare provider may prescribe to treat your type 2 diabetes, and where and how these medications work in your body to lower blood glucose. Type 2 diabetes medications are taken orally (by mouth), by injection (inserted into the fat under your skin), or inhaled (breathed in). Oral Injectable Alpha-glucosidase inhibitors (acarbose, miglitol) Amylin mimetic (pramlintide) Help to slow down the breakdown of starches (such Helps to decrease the amount of glucose made by your liver. as bread and potatoes) and certain types of sugar (such as table sugar) from your food in your intestines: Helps to slow down the breakdown of foods in your stomach this slows down increases in blood glucose. and intestines: this slows down increases in blood glucose Biguanide (metformin) GLP-1 receptor agonists (albiglutide, dulaglutide, exenatide, liraglutide) Helps to decrease the amount of glucose made by your liver Help your pancreas to make more insulin: insulin helps to lower blood glucose Helps to improve the way that insulin works in your Help to decrease the amount of glucose made by your muscles: if your muscles are more sensitive to insulin, it liver is easier for insulin to bring glucose from your blood into Helps to slow down the breakdown of foods in your muscles where glucose can be used for energy your stomach and intestines: this slows down increases in blood glucose DPP-4 inhibitors (alogliptin, linagliptin, saxagliptin, sitagliptin) Fat Tissue
    [Show full text]
  • Glycemic Management of Type 2 Diabetes
    Glycemic Management of Type 2 Diabetes Gail Nunlee-Bland, M.D. Professor Medicine & Pediatrics Director, Diabetes Treatment Center Howard University 1 Disclosures • None Learning Objectives • Understand the importance of lifestyle therapy in diabetes management • Know the classes of antihyperglycemic agents, mechanism of action, benefits and side effects of these agents • Recognize the importance of individualized treatment goals for diabetic patients AACE Comprehensive Care Plan Disease management from Antihyperglycemic a multidisciplinary team pharmacotherapy Comprehensive Care Plan Comprehensive diabetes Therapeutic lifestyle self-education for the change patient 4 Handelsman YH, et al. Endocr Pract. 2015;21(suppl 1):1-87. Glycemic Management of Type 2 Diabetes THERAPEUTIC LIFESTYLE CHANGE 5 Components of Therapeutic Lifestyle Change • Healthful eating • Sufficient physical activity • Sufficient sleep • Avoidance of tobacco products • Limited alcohol consumption • Stress reduction 6 Handelsman YH, et al. Endocr Pract. 2015;21(suppl 1):1-87. Glycemic Management of Type 2 Diabetes ANTIHYPERGLYCEMIC THERAPY 7 Cardiovascular Outcomes Trials: A Brief History • 2008 FDA guidance mandating assessment of CV safety of all antihyperglycemic agents in RCTs – Designed as noninferiority studies to demonstrate study drug was not associated with more MACE than placebo • Some study designs tested for superiority if noninferiority criteria were met – Primary endpoint: composite of cardiovascular death, nonfatal MI, and nonfatal stroke • Some primary
    [Show full text]
  • Standards of Medical Care in Diabetes—2019
    S90 Diabetes Care Volume 42, Supplement 1, January 2019 9. Pharmacologic Approaches to American Diabetes Association Glycemic Treatment: Standards of Medical Care in Diabetesd2019 Diabetes Care 2019;42(Suppl. 1):S90–S102 | https://doi.org/10.2337/dc19-S009 The American Diabetes Association (ADA) “Standards of Medical Care in Diabetes” includes ADA’s current clinical practice recommendations and is intended to provide the components of diabetes care, general treatment goals and guidelines, and tools to evaluate quality of care. Members of the ADA Professional Practice Committee, a multidisciplinary expert committee, are responsible for updating the Standards of Care annually, or more frequently as warranted. For a detailed description of ADA standards, statements, and reports, as well as the evidence-grading system for ADA’s clinical practice recommendations, please refer to the Standards of Care Introduction. Readers who wish to comment on the Standards of Care are invited to do so at professional.diabetes.org/SOC. PHARMACOLOGIC THERAPY FOR TYPE 1 DIABETES Recommendations 9.1 Most people with type 1 diabetes should be treated with multiple daily 9. PHARMACOLOGIC APPROACHES TO GLYCEMIC TREATMENT injections of prandial and basal insulin, or continuous subcutaneous insulin infusion. A 9.2 Most individuals with type 1 diabetes should use rapid-acting insulin analogs to reduce hypoglycemia risk. A 9.3 Consider educating individuals with type 1 diabetes on matching prandial insulin doses to carbohydrate intake, premeal blood glucose levels, and anticipated physical activity. E 9.4 Individuals with type 1 diabetes who have been successfully using continuous subcutaneous insulin infusion should have continued access to this therapy after they turn 65 years of age.
    [Show full text]